--News Direct--
Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today.
The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients.
Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies.
While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer.
Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers.
Click here to read Silexion's full announcement
***
This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest.
Contact Details
News Coverage
ronald@futuremarketsresearch.com
View source version on newsdirect.com: https://newsdirect.com/news/market-alert-silexion-therapeutics-nasdaq-slxn-sees-record-volumes-following-breakthrough-preclinical-data-for-sil-204-657423548
